Screening women aged 65 years or over for abdominal aortic aneurysm: a modelling study and health economic evaluation A discrete event simulation model was developed to provide a clinically realistic model of screening, surveillance, and elective and emergency AAA repair operations. Input parameters specifically for women were employed. The model was run for 10 million women, with parameter uncertainty addressed by probabilistic and deterministic sensitivity analyses. The accepted criteria for a population-based AAA screening programme in women are not currently met. Health Technology Assessment
with selected urea cycle disorders who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. Glycerol phenylbutyrate must be used with dietary protein restriction and, in some cases, dietary supplements (e.g. essential amino acids, arginine, citrulline, protein-free calorie supplements). SMC advice Systematic search: No August 2018 https://www.scottishmedicines.org.uk/medicines-advice/glycerol-phenylbutyrateravicti-fullsubmission-134218/ conestat alfa (Ruconest) conestat alfa is accepted for use within NHS Scotland for treatment of acute angioedema attacks in adults and adolescents with hereditary angioedema due to C1 esterase inhibitor deficiency. SMC 
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Youth health services -reviewing the benefits of a holistic approach
Using existing primary and review-level evidence, this briefing aims to evaluate the impact of youth health services which encourage young people's appropriate use of clinical services by co-locating them with other youth friendly health promotion activities. Rapid Review Systematic search: Limited August 2018 http://www.healthscotland.scot/publications/youth-health-services-reviewing-thebenefits-of-a-holistic-approach Social prescribing resources Social prescribing is an approach used to support self-management. It is primarily used for connecting people to non-medical sources of support or resources within their community. It can also be used by professionals working in other services and enhances the holistic approaches to addressing health, wellbeing and mental health problems. The resources here include a background paper, a guidance paper, written case studies and video case studies. Health Scotland Guidance Systematic search: No August 2018 http://www.healthscotland.scot/publications/social-prescribing-resources NICE NG102 Community pharmacies: promoting health and wellbeing This guideline covers how community pharmacies can help maintain and improve people's physical and mental health and wellbeing, including people with a long-term condition. It aims to encourage more people to use community pharmacies by integrating them within existing health and care pathways and ensuring they offer standard services and a consistent approach. It requires a collaborative approach from individual pharmacies and their representatives, local authorities and other commissioners. NICE Guideline Systematic search: Yes August 2018 https://www.nice.org.uk/guidance/ng102
NG103 Flu vaccination: increasing uptake
This guideline covers how to increase uptake of the free flu vaccination among people who are eligible. It describes ways to increase awareness and how to use all opportunities in primary and secondary care to identify people who should be encouraged to have the vaccination. NICE Guideline Systematic search: Yes August 2018 https://www.nice.org.uk/guidance/ng103 TA534 Dupilumab for treating moderate to severe atopic dermatitis Dupilumab is recommended as an option for treating moderate to severe atopic dermatitis in adults, only if the disease has not responded to at least 1 other systemic therapy, such as ciclosporin, methotrexate, azathioprine and mycophenolate mofetil, or these are contraindicated or not tolerated. Stop dupilumab at 16 weeks if the atopic dermatitis has not responded adequately. NICE Technology Appraisal Systematic search: Yes August 2018 https://www.nice.org.uk/guidance/ta534 TA535 Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine Lenvatinib and sorafenib are recommended as options for treating progressive, locally advanced or metastatic differentiated thyroid cancer (papillary, follicular or Hürthle cell) in adults whose disease does not respond to radioactive iodine, only if they have not had a tyrosine kinase inhibitor before or they have had to stop taking a tyrosine kinase inhibitor within 3 months of starting it because of toxicity (specifically, toxicity that cannot be managed by dose delay or dose modification). NICE Technology Appraisal Systematic search: Yes August 2018 https://www.nice.org.uk/guidance/ta535
TA536 Alectinib for untreated ALK-positive advanced non-small-cell lung cancer
Alectinib is recommended as an option for untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer in adults. NICE Technology Appraisal Systematic search: Yes August 2018 https://www.nice.org.uk/guidance/ta536 TA537 xekizumab for treating active psoriatic arthritis after inadequate response to DMARDs Ixekizumab alone, or with methotrexate, is recommended as an option for treating active psoriatic arthritis in adults, only if it is used as described in NICE's technology appraisal guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (TA199), or the person has had a TNF-alpha inhibitor but their disease has not responded within the first 12 weeks or has stopped responding after the first 12 weeks, or TNF-alpha inhibitors are contraindicated. NICE Technology Appraisal Systematic search: Yes August 2018 https://www.nice.org.uk/guidance/ta537 TA538 Dinutuximab beta for treating neuroblastoma Dinutuximab beta is recommended as an option for treating high-risk neuroblastoma in people aged 12 months and over whose disease has at least partially responded to induction chemotherapy, followed by myeloablative therapy and stem cell transplant, only if they have not already had anti-GD2 immunotherapy. NICE Technology Appraisal Systematic search: Yes August 2018 https://www.nice.org.uk/guidance/ta538 TA539 Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours Lutetium (177Lu) oxodotreotide is recommended as an option for treating unresectable or metastatic, progressive, well-differentiated (grade 1 or grade 2), somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours in adults. NICE Technology Appraisal Systematic search: Yes August 2018 https://www.nice.org.uk/guidance/ta539 EPPI Centre
Self-care for minor ailments
The broad aim of these three reviews and their overarching synthesis is to explore the factors that may enhance, or limit, the effectiveness of interventions or services designed to promote self-care for minor ailments and to synthesise evaluations of existing interventions/services to estimate their effectiveness. The review findings suggest interventions should be multi-modal; educational interventions on their own are unlikely to be effective. A range of feasible interventions, based on the behavioural analysis, could be implemented and tested for effectiveness in practice. Existing effective behaviour change interventions should continue to be supported, including issuing back-up (delayed) antibiotic prescriptions for minor conditions. Evidence Report Systematic search: Yes August 2018 http://eppi.ioe.ac.uk/cms/Default.aspx?tabid=3728
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